Literature DB >> 11689795

T2 tumors larger than five centimeters in diameter can be upgraded to T3 in non-small cell lung cancer.

E Carbone1, H Asamura, H Takei, H Kondo, K Suzuki, E Miyaoka, R Tsuchiya, G Motta.   

Abstract

OBJECTIVE: Among the TNM criteria, tumor size is a well-assessed factor in the prognosis of small tumors. A 3-cm cutoff point separates T1 from T2 tumors, whereas a size larger than 3 cm is not ascribed any prognostic value. Instead, N2 is considered to be the worst prognostic factor for intrathoracic extended disease.
METHOD: The prognosis of 545 patients with non-small cell lung cancer larger than 3 cm in diameter (T2, T3, and T4) was studied. These tumors were completely resected by pneumonectomy (n = 126) or lobectomy (n = 411) or were partially resected (n = 8). Survivals were compared according to the following factors: tumor size (3.1-5 cm, 5.1-7 cm, >7 cm), nodal status, age, sex, histologic type, degree of pleural involvement, operative procedure, stage, and T factor. For the multivariate analysis, the Cox proportional hazard model was used with the same variables.
RESULTS: The univariate analysis showed that age, sex, degree of pleural involvement, operative procedure, tumor size, nodal status, and stage were all significant prognostic factors. Further comparison of survival between different tumor sizes (< or =5 cm vs >5 cm) in the same nodal category demonstrated a significantly poor prognosis for larger tumors in N0 (P =.00374) and N2+N3 (P =.0157), but not in N1 (P =.3452). T2 tumors (n = 349) were divided, according to size, into T2a (n = 238) and T2b (n = 111), and survival was compared with those in T3 and T4. The 5-year survivals were 51.3%, 35.1%, 47.8%, and 25.3%, respectively. The difference between T2a and T2b was statistically significant (log-rank P =.0170, Breslow P =.0055).
CONCLUSIONS: A tumor size of more than 5 cm in diameter was indicative of a poor prognosis in non-small cell lung cancer, because patients with T2b tumors had a significantly different survival from that of patients with T2a tumors, and the survival curve was located between those for patients with T3 and T4 tumors. Consequently, T2b might be upgraded to at least T3.

Entities:  

Mesh:

Year:  2001        PMID: 11689795     DOI: 10.1067/mtc.2001.116949

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  3 in total

1.  Surgical Outcome of Video-Assisted Thoracoscopic Surgery vs. Thoracotomy for Primary Lung Cancer >5 cm in Diameter.

Authors:  Tomoyuki Nakano; Shunsuke Endo; Tetsuya Endo; Shinichi Otani; Hiroyoshi Tsubochi; Shinichi Yamamoto; Kenji Tetsuka
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-05-25       Impact factor: 1.520

Review 2.  A decade of advances in treatment of early-stage lung cancer.

Authors:  Luca Paoletti; Nicholas J Pastis; Chadrick E Denlinger; Gerard A Silvestri
Journal:  Clin Chest Med       Date:  2011-10-07       Impact factor: 2.878

3.  Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC.

Authors:  Daniel Morgensztern; Lingling Du; Saiama N Waqar; Aalok Patel; Pamela Samson; Siddhartha Devarakonda; Feng Gao; Cliff G Robinson; Jeffrey Bradley; Maria Baggstrom; Ashiq Masood; Ramaswamy Govindan; Varun Puri
Journal:  J Thorac Oncol       Date:  2016-06-08       Impact factor: 15.609

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.